SKP1: A Potential Drug Target for Cancer and Other Diseases (G6500)

Target Name: SKP1

NCBI ID: G6500

SKP1

SKP1: A Potential Drug Target for Cancer and Other Diseases

SKP1 (Cyclin A/CDK2-associated protein p19) is a protein that is expressed in various tissues throughout the body, including the brain, lungs, heart, and gastrointestinal tract. It is a key regulator of the cell cycle, and is involved in the development and progression of many diseases, including cancer.

SKP1 has been identified as a potential drug target for several reasons. Firstly, it is involved in the regulation of the cell cycle, which is a critical process for the development and progression of cancer. Secondly, SKP1 has been shown to play a role in the regulation of cell adhesion, which is important for the development of many diseases, including cancer.

SKP1 is a protein that is expressed in a wide range of tissues throughout the body, including the brain, lungs, heart, and gastrointestinal tract. It is a key regulator of the cell cycle, and is involved in the development and progression of many diseases , including cancer.

SKP1 has been shown to play a role in the regulation of the cell cycle by promoting the growth and division of cells. It does this by interacting with the protein CDK2, which is a key regulator of the cell cycle. SKP1 and CDK2 work together to promote the growth and division of cells by activating the G1 and S phases of the cell cycle.

SKP1 has also been shown to play a role in the regulation of cell adhesion by interacting with the protein PDGFR-尾. PDGFR-尾 is a protein that is involved in the regulation of cell adhesion, and is a potential drug target for cancer. SKP1 and PDGFR-尾 work together to promote the development of cancer by inhibiting the ability of cells to stick to each other.

SKP1 is also involved in the regulation of many other processes in the body, including the regulation of inflammation and the immune response. It is also involved in the regulation of the production of hormones, which is important for the development and progression of many diseases, including cancer.

SKP1 is a protein that is involved in the regulation of the cell cycle, cell adhesion, and many other processes in the body. It is a potential drug target for cancer and other diseases. Further research is needed to fully understand the role of SKP1 in these processes and to develop effective treatments.

Protein Name: S-phase Kinase Associated Protein 1

Functions: Essential component of the SCF (SKP1-CUL1-F-box protein) ubiquitin ligase complex, which mediates the ubiquitination of proteins involved in cell cycle progression, signal transduction and transcription. In the SCF complex, serves as an adapter that links the F-box protein to CUL1. The functional specificity of the SCF complex depends on the F-box protein as substrate recognition component. SCF(BTRC) and SCF(FBXW11) direct ubiquitination of CTNNB1 and participate in Wnt signaling. SCF(FBXW11) directs ubiquitination of phosphorylated NFKBIA. SCF(BTRC) directs ubiquitination of NFKBIB, NFKBIE, ATF4, SMAD3, SMAD4, CDC25A, FBXO5, CEP68 and probably NFKB2 (PubMed:25704143). SCF(SKP2) directs ubiquitination of phosphorylated CDKN1B/p27kip and is involved in regulation of G1/S transition. SCF(SKP2) directs ubiquitination of ORC1, CDT1, RBL2, ELF4, CDKN1A, RAG2, FOXO1A, and probably MYC and TAL1. SCF(FBXW7) directs ubiquitination of cyclin E, NOTCH1 released notch intracellular domain (NICD), and probably PSEN1. SCF(FBXW2) directs ubiquitination of GCM1. SCF(FBXO32) directs ubiquitination of MYOD1. SCF(FBXO7) directs ubiquitination of BIRC2 and DLGAP5. SCF(FBXO33) directs ubiquitination of YBX1. SCF(FBXO11) directs ubiquitination of BCL6 and DTL but does not seem to direct ubiquitination of TP53. SCF(BTRC) mediates the ubiquitination of NFKBIA at 'Lys-21' and 'Lys-22'; the degradation frees the associated NFKB1-RELA dimer to translocate into the nucleus and to activate transcription. SCF(CCNF) directs ubiquitination of CCP110. SCF(FBXL3) and SCF(FBXL21) direct ubiquitination of CRY1 and CRY2. SCF(FBXO9) directs ubiquitination of TTI1 and TELO2. SCF(FBXO10) directs ubiquitination of BCL2

The "SKP1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SKP1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets